As Wall Street tossed another would-be pancreatic cancer therapy on the phase III scrap heap, Newlink Genetics Corp. CEO Charles Link said the firm is "evaluating the future" of the Hyperacute Cellular Immunotherapy platform, from which emerged algenpantucel-L, most recently to fail in patients with resected tumors.